Racial and Ethnic Disparities in Ambulatory Heart Failure Ventricular Assist Device Implantation and Survival.
INTERMACS profile
ambulatory heart failure
health disparities
heart failure
racial disparities
ventricular assist device
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
02
12
2022
revised:
18
04
2023
accepted:
09
05
2023
pmc-release:
01
10
2024
medline:
1
11
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Durable left ventricular assist devices (VADs) improve survival in eligible patients, but allocation has been associated with patient race in addition to presumed heart failure (HF) severity. This study sought to determine racial and ethnic differences in VAD implantation rates and post-VAD survival among patients with ambulatory HF. Using the INTERMACS (Interagency Registry of Mechanically Assisted Circulatory Support) database (2012-2017), this study examined census-adjusted VAD implantation rates by race, ethnicity, and sex in patients with ambulatory HF (INTERMACS profile 4-7) using negative binomial models with quadratic effect of time. Survival was evaluated using Kaplan-Meier estimates and Cox models adjusted for clinically relevant variables and an interaction of time with race/ethnicity. VADs were implanted in 2,256 adult patients with ambulatory HF (78.3% White, 16.4% Black, and 5.3% Hispanic). The median age at implantation was lowest in Black patients. Implantation rates peaked between 2013 and 2015 before declining in all demographic groups. From 2012 to 2017, implantation rates overlapped for Black and White patients but were lower for Hispanic patients. Post-VAD survival was significantly different among the 3 groups (log rank P = 0.0067), with higher estimated survival among Black vs White patients (12-month survival: Black patients: 90% [95% CI: 86%-93%]; White patients: 82% [95% CI: 80%-84%]). Low sample size for Hispanic patients resulted in imprecise survival estimates (12-month survival: 85% [95% CI: 76%-90%]). Black and White patients with ambulatory HF had similar VAD implantation rates but rates were lower for Hispanic patients. Survival differed among the 3 groups, with the highest estimated survival at 12 months in Black patients. Given higher HF burden in minoritized populations, further investigation is needed to understand differences in VAD implantation rates in Black and Hispanic patients.
Sections du résumé
BACKGROUND
Durable left ventricular assist devices (VADs) improve survival in eligible patients, but allocation has been associated with patient race in addition to presumed heart failure (HF) severity.
OBJECTIVES
This study sought to determine racial and ethnic differences in VAD implantation rates and post-VAD survival among patients with ambulatory HF.
METHODS
Using the INTERMACS (Interagency Registry of Mechanically Assisted Circulatory Support) database (2012-2017), this study examined census-adjusted VAD implantation rates by race, ethnicity, and sex in patients with ambulatory HF (INTERMACS profile 4-7) using negative binomial models with quadratic effect of time. Survival was evaluated using Kaplan-Meier estimates and Cox models adjusted for clinically relevant variables and an interaction of time with race/ethnicity.
RESULTS
VADs were implanted in 2,256 adult patients with ambulatory HF (78.3% White, 16.4% Black, and 5.3% Hispanic). The median age at implantation was lowest in Black patients. Implantation rates peaked between 2013 and 2015 before declining in all demographic groups. From 2012 to 2017, implantation rates overlapped for Black and White patients but were lower for Hispanic patients. Post-VAD survival was significantly different among the 3 groups (log rank P = 0.0067), with higher estimated survival among Black vs White patients (12-month survival: Black patients: 90% [95% CI: 86%-93%]; White patients: 82% [95% CI: 80%-84%]). Low sample size for Hispanic patients resulted in imprecise survival estimates (12-month survival: 85% [95% CI: 76%-90%]).
CONCLUSIONS
Black and White patients with ambulatory HF had similar VAD implantation rates but rates were lower for Hispanic patients. Survival differed among the 3 groups, with the highest estimated survival at 12 months in Black patients. Given higher HF burden in minoritized populations, further investigation is needed to understand differences in VAD implantation rates in Black and Hispanic patients.
Identifiants
pubmed: 37389504
pii: S2213-1779(23)00253-6
doi: 10.1016/j.jchf.2023.05.017
pmc: PMC10614028
mid: NIHMS1936800
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1397-1407Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL142848
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL148881
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL159216
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007411
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL159216
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG063661
Pays : United States
Informations de copyright
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures This study was funded by the National Heart, Lung, and Blood Institute (R01HL159216, R56HL159216, K01HL142848, and L30HL148881) to Dr Breathett, and Health Resources and Services Administration PRIME to Dr Breathett. Dr Dixon has received support from the Training in Cardiovascular Research (T32 HL007411) and American College of Cardiology/Association of Black Cardiologists Bristol Myers Squibb Research Fellowship. Dr Lewsey has received support from the National Institute on Aging (3R01AG063661-03S1). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
N Engl J Med. 2001 Nov 15;345(20):1435-43
pubmed: 11794191
Circulation. 2018 Jul 3;138(1):12-24
pubmed: 29519849
Circ Heart Fail. 2019 Jan;12(1):e005377
pubmed: 30621509
Acad Med. 2017 Mar;92(3):365-369
pubmed: 27680316
JACC Heart Fail. 2018 May;6(5):413-420
pubmed: 29724363
J Am Coll Cardiol. 2014 May 6;63(17):1751-7
pubmed: 24613333
JAMA Netw Open. 2020 Jul 1;3(7):e2011044
pubmed: 32692370
Circulation. 2019 Feb 19;139(8):1080-1093
pubmed: 30779645
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Circulation. 2022 Feb 22;145(8):e153-e639
pubmed: 35078371
Open Heart. 2014 Aug 05;1(1):e000109
pubmed: 25332817
J Card Fail. 2019 Sep;25(9):735-743
pubmed: 31220624
Heart Lung. 2019 Mar - Apr;48(2):85-89
pubmed: 30227993
Circulation. 2021 Jun 15;143(24):2412-2414
pubmed: 34125563
Circ Heart Fail. 2019 Jul;12(7):e006058
pubmed: 31213069
Circ Heart Fail. 2014 Nov;7(6):1003-13
pubmed: 25294625
J Am Heart Assoc. 2021 Sep 7;10(17):e020146
pubmed: 34465163
J Am Heart Assoc. 2019 Nov 19;8(22):e013592
pubmed: 31707940
J Am Coll Cardiol. 2015 Oct 20;66(16):1747-1761
pubmed: 26483097
J Am Heart Assoc. 2023 Mar 7;12(5):e027701
pubmed: 36846988
J Am Coll Cardiol. 2019 May 14;73(18):2354-2355
pubmed: 31072580
JAMA Cardiol. 2020 Dec 1;5(12):1425-1429
pubmed: 32876652
Am J Transplant. 2023 Jun;23(6):805-814
pubmed: 36931436
Circ Heart Fail. 2023 Jan;16(1):e009745
pubmed: 36259388
Circulation. 2021 Oct 12;144(15):e238-e250
pubmed: 34503343
J Heart Lung Transplant. 2011 Apr;30(4):402-7
pubmed: 21168346
J Exp Soc Psychol. 2017 Nov;73:211-215
pubmed: 29249837
JAMA Intern Med. 2018 Apr 01;178(4):520-529
pubmed: 29482225
JAMA Netw Open. 2022 Jul 1;5(7):e2223080
pubmed: 35895063
Curr Opin Cardiol. 2021 May 1;36(3):340-351
pubmed: 33720052
Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7):
pubmed: 28655709
J Heart Lung Transplant. 2008 Oct;27(10):1065-72
pubmed: 18926395
N Engl J Med. 2009 Mar 19;360(12):1179-90
pubmed: 19297571
Arch Intern Med. 2008 Oct 27;168(19):2138-45
pubmed: 18955644
Ann Thorac Surg. 2021 Mar;111(3):778-792
pubmed: 33465365
J Heart Lung Transplant. 2019 Apr;38(4):408-417
pubmed: 30948210
Circ Heart Fail. 2018 Aug;11(8):e005008
pubmed: 30021796